Urine CXCL10 as a biomarker in kidney transplantation.
Curr Opin Organ Transplant
; 29(2): 138-143, 2024 04 01.
Article
en En
| MEDLINE
| ID: mdl-38235748
ABSTRACT
PURPOSE OF REVIEW Urine CXCL10 is a promising biomarker for posttransplant renal allograft monitoring but is currently not widely used for clinical management. RECENT FINDINGS:
Large retrospective studies and data from a prospective randomized trial as well as a prospective cohort study demonstrate that low urine CXCL10 levels are associated with a low risk of rejection and can exclude BK polyomavirus replication with high certainty. Urine CXCL10 can either be used as part of a multiparameter based risk assessment tool, or as an individual biomarker taking relevant confounders into account. A novel Luminex-based CXCL10 assay has been validated in a multicenter study, and proved to be robust, reproducible, and accurate.SUMMARY:
Urine CXCL10 is a well characterized inflammation biomarker, which can be used to guide performance of surveillance biopsies. Wide implementation into clinical practice depends on the availability of inexpensive, thoroughly validated assays with approval from regulatory authorities.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Trasplante de Riñón
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Curr Opin Organ Transplant
/
Curr. opin. organ transplant
/
Current opinion in organ transplantation
Año:
2024
Tipo del documento:
Article